Zugriffszahlen seit März 2016. Zugriffszahlen aus dem Vorgängersystem werden nicht mitberücksichtigt.

Total Visits

Views
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)38

Total Visits Per Month

November 2020December 2020January 2021February 2021March 2021April 2021May 2021
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)00008300

Top country views

Views

Top cities views

Views